China Money Network
Login
Join

Goldman Sachs Injects $20M In China Biotech Firm Ascletis

  • December 3, 2015 — 10:18 CST

This Data Is Locked!

This area is available only to Subscribers.

Hangzhou-based biotech firm Ascletis has received US$20 million from Goldman Sachs, bringing the company’s total fundraising to US$55 million, according to a company announcement. Ascletis... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: